MedTrace Logo

Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study

NCT06161415 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-05-14

No results posted yet for this study

Summary

The LION Study is a prospective, single-center phase 1 clinical trial to evaluate the safety, tolerability, and distribution of Laquinimod administered as topical eye drops for two weeks in human participants.

Conditions

Interventions

DRUG

Laquinimod eye drops

n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned

Sponsors & Collaborators

  • Global Ophthalmic Research Center (GORC)

    collaborator UNKNOWN

  • Quan Dong Nguyen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-03
Primary Completion
2025-07-31
Completion
2025-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06161415 on ClinicalTrials.gov